APO Research
Talk to an analyst

APO RESEARCH · REPORT

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis and Forecast 2026-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchIdiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Research Report 2026100 pages · $2,950 USDIndustry Growth & TrendsGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics include Grifols Biologicals Inc., Amgen Inc, GlaxoSmithKline Plc and Roch, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Company

Grifols Biologicals Inc.

Amgen Inc

GlaxoSmithKline Plc

Roch

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Type

Thrombopoietin Receptor Agonists (TPO-RA)

Corticosteroids

Anti-D Immunoglobulin

Intravenous Immunoglobulin (IVIG)

Others

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Application

Hospitals

Clinics

Others

Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Thrombopoietin Receptor Agonists (TPO-RA) Major Player Table 3. Corticosteroids Major Player Table 4. Anti-D Immunoglobulin Major Player Table 5. Intravenous Immunoglobulin (IVIG) Major Player Table 6. Others Major Player Table 7. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Clinics Major Player Table 10. Others Major Player Table 11. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Trends Table 12. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Drivers Table 13. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Opportunities and Challenges Table 14. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Restraints Table 15. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Region (2021-2026) Table 18. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Region (2027-2032) Table 20. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Players (2021-2026) Table 22. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Key Players Headquarters & Area Served Table 24. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players, Product Type & Application Table 25. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type (2021-2026) Table 32. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type (2027-2032) Table 33. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2021-2026) Table 37. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2027-2032) Table 38. Grifols Biologicals Inc. Company Information Table 39. Grifols Biologicals Inc. Business Overview Table 40. Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 42. Grifols Biologicals Inc. Recent Development Table 43. Amgen Inc Company Information Table 44. Amgen Inc Business Overview Table 45. Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 47. Amgen Inc Recent Development Table 48. GlaxoSmithKline Plc Company Information Table 49. GlaxoSmithKline Plc Business Overview Table 50. GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 52. GlaxoSmithKline Plc Recent Development Table 53. Roch Company Information Table 54. Roch Business Overview Table 55. Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio Table 57. Roch Recent Development Table 58. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 59. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 60. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 61. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 62. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 63. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 64. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 65. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 66. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 67. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 68. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 69. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 70. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 71. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 72. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 73. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 74. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 75. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 76. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 77. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 78. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 79. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 80. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 81. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 82. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 83. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 84. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 85. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 86. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 87. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 89. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Image Figure 2. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Thrombopoietin Receptor Agonists (TPO-RA) Image Figure 5. Corticosteroids Image Figure 6. Anti-D Immunoglobulin Image Figure 7. Intravenous Immunoglobulin (IVIG) Image Figure 8. Others Image Figure 9. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Clinics Image Figure 13. Others Image Figure 14. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (US$ Million) & (2021-2032) Figure 15. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type (2021-2032) Figure 22. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2021-2032) Figure 25. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032) Figure 27. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032) Figure 28. North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Country (2021-2032) Figure 29. United States Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032) Figure 34. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032) Figure 35. Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Country (2021-2032) Figure 36. Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032) Figure 46. China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032) Figure 49. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032) Figure 50. Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Region (2021-2032) Figure 51. Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032) Figure 59. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032) Figure 60. SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Country (2021-2032) Figure 61. Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Thrombopoietin Receptor Agonists (TPO-RA)
  • Corticosteroids
  • Anti-D Immunoglobulin
  • Intravenous Immunoglobulin (IVIG)
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Grifols Biologicals Inc.
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Roch

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Type
  3. 1.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Thrombopoietin Receptor Agonists (TPO-RA)
  5. 1.2.3 Corticosteroids
  6. 1.2.4 Anti-D Immunoglobulin
  7. 1.2.5 Intravenous Immunoglobulin (IVIG)
  8. 1.2.6 Others
  9. 1.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market by Application
  10. 1.3.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Clinics
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Dynamics
  1. 2.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Trends
  2. 2.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Drivers
  3. 2.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Growth Trends by Region
  3. 3.2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Players
  2. 4.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players, Product Type & Application
  8. 4.5 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Tier 1, Tier 2, and Tier 3
5 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type
  1. 5.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Type (2021-2032)
6 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application
  1. 6.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Grifols Biologicals Inc.
  2. 7.1.1 Grifols Biologicals Inc. Company Information
  3. 7.1.2 Grifols Biologicals Inc. Business Overview
  4. 7.1.3 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  6. 7.1.5 Grifols Biologicals Inc. Recent Developments
  7. 7.2 Amgen Inc
  8. 7.2.1 Amgen Inc Company Information
  9. 7.2.2 Amgen Inc Business Overview
  10. 7.2.3 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  12. 7.2.5 Amgen Inc Recent Developments
  13. 7.3 GlaxoSmithKline Plc
  14. 7.3.1 GlaxoSmithKline Plc Company Information
  15. 7.3.2 GlaxoSmithKline Plc Business Overview
  16. 7.3.3 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  18. 7.3.5 GlaxoSmithKline Plc Recent Developments
  19. 7.4 Roch
  20. 7.4.1 Roch Company Information
  21. 7.4.2 Roch Business Overview
  22. 7.4.3 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Portfolio
  24. 7.4.5 Roch Recent Developments
8 North America
  1. 8.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (2021-2032)
  2. 8.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country
  11. 8.6.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country
  11. 9.6.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (2021-2032)
  2. 10.2 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country
  11. 11.6.1 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst